stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) Net income
Corcept Therapeutics Incorporated's net income for fiscal 2025 was $99.7M, down 29.4% from $141.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $162.3M. Over the past ten years it has ranged from −$6.4M (fiscal 2015) to $141.2M (fiscal 2024); the current reading is higher than 45% of that period. Corcept Therapeutics Incorporated ranks 28th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $99.7M | (29.43%) |
| FY2024 | $141.2M | 33.04% |
| FY2023 | $106.1M | 4.66% |
| FY2022 | $101.4M | (9.86%) |
| FY2021 | $112.5M | 6.13% |
| FY2020 | $106.0M | 12.56% |
| FY2019 | $94.2M | 24.89% |
| FY2018 | $75.4M | (41.60%) |
| FY2017 | $129.1M | 1,486.27% |
| FY2016 | $8.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $126.8M | 194.92% |
| Jun 2026 | $43.0M | — |
| Mar 2026 | −$31.8M | — |
| Dec 2025 | $24.3M | 23.49% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $225.2M |
| CORT Corcept Therapeutics Incorporated | $162.3M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$155.5M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$272.1M |
| PRAX Praxis Precision Medicines, Inc. compare | −$339.1M |
| ABVX Abivax SA Sponsored ADR compare | −$458.7M |
| CYTK Cytokinetics, Incorporated compare | −$777.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on CORT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement